Almirall shares new dermatology data at EADV 2026

The company said its programme at the 35th European Academy of Dermatology and Venereology Congress in Vienna includes more than 20 abstracts, late-breaking data and two expert symposia. It highlighted new evidence for lebrikizumab, tildrakizumab, CAL/BDP PAD cream and tirbanibulin across atopic dermatitis, psoriasis and actinic keratosis.